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illusTraTive case 
An otherwise healthy, sexually active  
21-year-old woman complains of pelvic 
pain for a week and yellow vaginal  
discharge. The history and physical exam 
are consistent with mild, uncomplicated 
pelvic inflammatory disease (PID). 
You believe outpatient therapy is  
appropriate in this case and wonder if  
there is a better alternative to doxycycline,  
particularly given the challenges of  
adherence to the recommended  
14-day course of treatment.
Background  
z		2	doses	or	28	doses?
In the real world, we know that adher-
ence is better when patients have to take 
2 pills than when they have to take 28 
pills. For most women with mild, un-
complicated PID, outpatient treatment 
is appropriate2 and a shorter treatment 
course is related to better adherence.3 
Azithromycin can be given in 2 single 
doses a week apart, with few side effects, 
and its spectrum of activity is similar to 
that of doxycycline,4 which requires a 
14-day regimen of 2 pills daily. Earlier 
studies of azithromycin for PID, how-
ever, were not designed specifically for 
outpatient treatment, or had methodo-
logic bias.5 Thus, the evidence has been 
insufficient to recommend it.
PID affects about 1 million women in 
the US each year, and can cause pain, scar-
ring of the fallopian tubes, and infertility.
current recommendations. The Cen-
ters for Disease Control and Prevention 
(CDC) recommends oral doxycycline 100 
mg twice daily for 14 days, along with a 
second- or third-generation cephalosporin 
administered parenterally, for mild PID 
in ambulatory patients.5 Metronizadole 
can be added at the provider’s discretion. 
The CDC no longer routinely recommends 
fluoroquinolones for PID because of gono-
coccal resistance.6 Dynamed, PEPID PCP, 
and UpToDate all cite CDC guidelines. 
Dynamed also notes results of the article 
reviewed here, though treatment recom-
mendations were not changed.7–9
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outpatient treatment of 
patients with mild pelvic 
inflammatory disease, using 
1 g of azithromycin weekly 
for 2 weeks, combined with 
250 mg of ceftriaxone 
intramuscularly on the first 
day, is superior to the current 
recommended treatment with 
doxycycline plus ceftriaxone.1 
Strength of recommendation (Sor) 
a: Single well-designed rcT
Savaris rF, Teixeira lm, Torres TG, edelweiss mI, 
moncada J, Schachter J. comparing ceftriaxone 
plus azithromycin or doxycycline for pelvic inflam-
matory disease: a randomized controlled trial. 
Obstet Gynecol 2007; 110:53–60.
Practice changer 
Azithromycin  
was superior  
to doxycycline 
in all clinical  
and laboratory 
comparisons
PURLS methodology
The criteria and findings  
leading to the selection of  
this study as a Priority Update 
from the Research Literature 
can be accessed at  
www.jfponline.com/purls.
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This RCT shows 
that azithromycin 
is superior to  
doxycycline even 
when compliance 
in taking  
doxycycline is  
excellent (which  
is not the reality  
in clinical practice)
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a simpler approach  
to pelvic inflammatory disease  
Patients will likely find it easier  
to take 1 azithromycin pill initially  
and 1 pill a week later, than to take  
a doxycycline pill twice daily  
for 14 days. lf so, then  
the advantage of azithromycin 
could be greater than  
reported in this study 
clinical conTexT 
z			First	comparison	study,	
first	outpatient	study
The study by Savaris and colleagues is 
the first comparison study of azithro-
mycin and doxycycline for PID, and the 
first study of outpatient treatment of 
PID with azithromycin.
An earlier study reported that 
women with PID who were prescribed 
doxycycline took an average of 70% 
of the total doses, and fewer than half 
took it twice daily as directed.3 
Azithromycin is known to be ef-
fective for treatment of Chlamydia 
trachomatis cervical infections,4 and 
single-dose azithromycin has been also 
been shown to have better compliance 
than multidose therapy for Chlamydia 
infection.10
We identified only 1 prior random-
ized controlled trial of azithromycin for 
treatment of PID. That trial reported 
that intravenous azithromycin followed 
by oral azithromycin with or without 
metronidazole is effective in the treat-
ment of PID.11 
sTudy summary  
z		Azithromycin	cure	rate	
90%,	doxycycline	72%
This randomized, double-blind, con-
trolled study evaluated the effectiveness 
of azithromycin plus ceftriaxone in the 
treatment of mild, uncomplicated PID 
compared to doxycycline plus ceftriax-
one, in outpatients.
Patients
The study enrolled 133 women who 
presented to an emergency department 
with PID diagnosed by the following 
clinical criteria: 
• pelvic pain for less than 30 days
• pelvic organ (adnexal or cervical) 
tenderness on physical examination
•  cervical leukorrhea or mucopuru-
lent cervicitis. 
Method
The women were randomized into 
2 groups, and both groups received 
250 mg of ceftriaxone intramuscularly. 
• The control group received 100 mg 
of doxycycline twice daily for 2 weeks.  
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• The study group received 1 g of 
azithromycin by mouth weekly for 
2 weeks and a placebo twice daily 
for 2 weeks to maintain blinding.
Outcomes
The primary outcome was clinical cure 
after 2 weeks of treatment. Clinical 
cure was defined as an improvement in 
pain scale ratings by 70%. Failure was 
defined as worsening of pain, lack of 
improvement of pain, or need for 
additional antibiotic therapy, hospital-
ization, or surgery.
Of the 133 women randomized, 
13 (9 from the azithromycin group and 
4 from the doxycycline group) were 
found to have diagnoses other than PID 
after randomization.  
intention-to-treat analysis was per-
formed for the remaining 120 partici-
pants.  In the azithromycin group, 56/62 
(90.3%; 95% confidence interval [CI], 
0.80–0.96) women were classified as 
clinically cured, versus 42/58 (72.4%; 
95% CI, 0.58–0.82) in the doxycycline 
group. 
adverse events. Except for oral in-
tolerance to the first dose of medication, 
which was similar in both groups, ad-
verse events were not reported.
Adherence	similar		
in	both	groups
Adherence to the study protocol was 
similar in both groups. The study au-
thors concluded that azithromycin was 
superior to doxycycline even though the 
adherence in the doxycycline group was 
good.
whaT’s new?  
z			Better	adherence	
is	the	probable	bonus
This RCT shows that azithromycin 
treatment of PID in an ambulatory 
population is superior to doxycycline 
even when there is excellent compliance 
with taking doxycycline (unlike the re-
ality of clinical practice). The patients 
in this RCT adhered well to the pro-
tocol, so it does not provide a realistic 
head-to-head comparison of treatment 
completion.
Real-world	adherence
In actual practice, we speculate that 
taking 2 pills 1 week apart will be 
much easier for patients than taking 
2 pills every day for 14 days. The litera-
ture on compliance would predict that 
to be the case. If true, then the advan-
tage of azithromycin over doxycycline 
would be even greater than reported in 
this study.
caveaTs  
z		Apply	these	findings	
in	similar	cases	only
This study addresses ambulatory treat-
ment of mild, uncomplicated PID, and 
results should only be extrapolated to 
similar cases. 
Azithromycin should not be pre-
scribed to patients with an allergy to 
macrolide antibiotics
One of the study authors received 
azithromycin donated by Pfizer for other 
research; however, Pfizer did not sponsor 
this study.
challenges To imPlemenTaTion  
z		Cost	of	the	prescription
Prescription cost may be a consider-
ation for patients without insurance, 
although azithromycin has been shown 
to be cost-effective in treatment of 
Chlamydia.12 
z		Reminding	patients	
to	take	the	second	dose
Some patients may have difficulty re-
membering to take the second dose a 
week after the first dose. 
A follow-up visit, reminder phone 
call, or suggestion to “mark this on 
your calendar” may help enhance 
adherence.  n
In an earlier study, 
fewer than half  
of women with PID 
took doxycycline  
twice daily as 
directed
www.jfponline.com
Purls methodology
This study was selected and evaluated using the Family Physician 
Inquiries Network’s Priority Updates from the research literature 
Surveillance System (PUrls) methodology. The criteria and find-
ings leading to the selection of this study as a PUrl can be ac-
cessed at www.jfponline.com/purls.
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3  do you have trouble keeping up with  
advances that you ought to put into practice?  
3  do you feel powerless to sift through  
all the guidelines, meta-analyses, and  
controlled trials? 
3  are you looking for authoritative updates,  
with take-home points?
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Then turn to Purls —Priority updates from  
the research literature 
each month the PUrls staff, from the University of  
chicago and the Family Physicians Inquiries Network 
(FPIN), scans new research, looking for those few articles 
that we really should put into practice immediately. Using 
a rigorous screening and selection process, we review and 
interpret the most relevant and authoritative sources of 
evidence-based medicine. 
but you—the practicing physician—have a decisive vote  
on what gets picked as a PUrls topic. 
you can be a “reality checker” 
If you are in full-time clinical practice, a medical director  
of a practice, or otherwise directly involved in decision-
making about adopting new practices, join our team of 
“reality checkers.” 
interested? Just email me  
at be.editor@gmail.com
Bernard ewigman, md, msPh
Department of Family medicine,  
The University of chicago
where research  
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